Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases.
More about this company
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. The company was incorporated in 2018 and is based in Fremont, California.
Sector: health
Conviction from: NASDAQ
52-week range: 18.8438.54
2 tracked filer(s) hold this · 2 opened, 0 added, 0 trimmed in 30-JUN-2026
Aggregate 13FScore 54 — mean of 2 scored holder(s) · buyers (new/add) avg 54. Higher = the smart money in this name has the better track record.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-04-23 | SCHEDULE 13D | Illumina Innovation Fund II, L.P. | 9.6% | Med | filing |
| 2026-04-23 | SCHEDULE 13D | Sands Capital Life Sciences Pulse Fund II, L.P. | 6.3% | Med | filing |
| Filed | Insider | Role | Shares | Value | |
|---|
| 2026-04-20 | Illumina Innovation Fund II GP, L.L.C. (cluster of 2) | 10%-owner | 235,294 | $3,999,998 | Form 4 |
| 2026-04-20 | Naclerio Nicholas (cluster of 2) | director | 235,294 | $3,999,998 | Form 4 |